Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Jan-Feb;67(1):50-53.
doi: 10.4103/ijd.ijd_249_21.

Azathioprine-Induced Marrow Suppression in Dermatology Patients - Analysis of 18 Patients

Vikrant V Saoji  1 , Sugat A Jawade  1 , Piyush Agrawal  2 , Shravya Rimmalapudi  1
Affiliations
Case Reports

Azathioprine-Induced Marrow Suppression in Dermatology Patients - Analysis of 18 Patients

Vikrant V Saoji et al. Indian J Dermatol. 2022 Jan-Feb.

Abstract

Background: Azathioprine is an immunosuppressant used to treat several immunological disorders. As a purine analog, it inhibits DNA synthesis and cell multiplication. However, marrow suppression is a serious complication associated with azathioprine.

Aim: To analyze the marrow suppression caused by azathioprine in dermatology patients.

Material and method: This is a retrospective analysis of the records of 18 patients who presented with marrow suppression secondary to azathioprine which was used for the treatment of various dermatological diseases.

Results: The analysis includes 18 patients, 15 females and 3 males with the average age being 25.88 years. All except two patients received 1 mg/kg of oral azathioprine once daily. Leukopenia was seen in 13 patients (with severe leukopenia in 7 patients), thrombocytopenia in 8, and low hemoglobin in 14 patients. Isolated low hemoglobin was seen in four patients, isolated leukopenia in four patients, and only one patient presented with isolated thrombocytopenia. Six patients had pancytopenia. The duration from the starting dose to reporting of marrow suppression ranged from 10 days to 1 year. Eight out of 18 patients presented with anagen effluvium, 2 patients with oral ulcers, and 1 patient with an upper respiratory tract infection. All the patients recovered within 1 month.

Conclusion: Marrow suppression due to azathioprine can occur with a low dose of 1 mg/kg. Hair loss and oral ulcers serve as early warning signs for marrow suppression.

Keywords: Azathioprine; immunosuppressant; myelotoxicity.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Similar articles

See all similar articles

Cited by

References

    1. Badalamenti SS, Kerdel FA. Azathioprine. In: Wolverton SE, editor. Comprehensive Dermatologic Drug Therapy. Philadelphia: Saunders; 2013. pp. 182–9.
    1. Radmanesh M, Saedi K. The efficacy of combined PUVA and low-dose azathioprine for early and enhanced repigmentation in vitiligo patients. J Dermatolog Treat. 2006;17:151–3. - PubMed
    1. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut. 1993;34:1081–5. - PMC - PubMed
    1. Anstey AV, Wakelin S, Reynolds NJ. British Association of Dermatologists therapy, guidelines and audit subcommittee. Br J Dermatol. 2004;151:1123–32. - PubMed
    1. Ambar G, Vandana A, Lalit D, Jyoti K. Thiopurine S-methyltransferase (TPMT) mutation prevalence and myelosuppression frequency in North Indian patients with autoimmune disorders. J Association Physicians India. 2018;66:39–44. - PubMed

Publication types